S Censi1, J Manso1, G Pandolfo1, G Franceschet1, E Cavedon1, Y H Zhu1, S Carducci1, W Gomiero2, M Plebani3, M Zaninotto3, S Watutantrige-Fernando1, C Mian1, V Camozzi4. 1. Endocrinology Unit, Department of Medicine (DIMED), Università di Padova, Via Ospedale n. 105, 35128, Padua, Italy. 2. Sport and Exercise Medicine Division, Department of Medicine (DIMED), Università di Padova, Padua, Italy. 3. Laboratory Medicine, Department of Medicine (DIMED), Università di Padova, Padua, Italy. 4. Endocrinology Unit, Department of Medicine (DIMED), Università di Padova, Via Ospedale n. 105, 35128, Padua, Italy. valentina.camozzi@unipd.it.
Abstract
PURPOSE: Chronic GC administration has numerous side effects, but little is known about the side effects of their short-term use (< 3 months)-particularly, when high doses are involved, as in the treatment of Graves' orbitopathy (GO). We investigated the effects of short-term, high-dose GC on bone turnover markers, bone mineral density (BMD), and trabecular bone scores (TBS). METHODS: Eleven patients (10 females and 1 male; median age 56 years) with active GO who were candidates for treatment with intravenous (iv) methylprednisone were consecutively enrolled. All patients were pretreated with a loading dose of 300,000 units of cholecalciferol, then given a median cumulative dose of 4.5 g (range 1.5-5.25 g) iv methylprednisone. Biochemical parameters of bone metabolism (25OHD3, PTH, P1NP, CTX and bALP) were measured at the baseline, and then 1 week and 1, 3, 6 and 12 months. BMD and TBS were obtained by X-ray absorptiometry (DXA) at the baseline and at 6 and 12 months. On DXA image, morphometric vertebral fracture assessment (VFA) was done. RESULTS: There were no significant changes in PTH, bALP or P1NP. A significant drop in CTX was seen at 1 month (down Δ49.31% from the baseline, p = 0.02), with a return to the baseline at the 3-month measurement. There was a moderate (not significant), but persistent reduction in P1NP. No changes in BMD or TBS came to light. No vertebral fractures were documented. CONCLUSIONS: Short-term, high-dose GC treatment caused a rapid, transient suppression of bone resorption, with no effects on BMD or bone micro-architecture (TBS).
PURPOSE: Chronic GC administration has numerous side effects, but little is known about the side effects of their short-term use (< 3 months)-particularly, when high doses are involved, as in the treatment of Graves' orbitopathy (GO). We investigated the effects of short-term, high-dose GC on bone turnover markers, bone mineral density (BMD), and trabecular bone scores (TBS). METHODS: Eleven patients (10 females and 1 male; median age 56 years) with active GO who were candidates for treatment with intravenous (iv) methylprednisone were consecutively enrolled. All patients were pretreated with a loading dose of 300,000 units of cholecalciferol, then given a median cumulative dose of 4.5 g (range 1.5-5.25 g) iv methylprednisone. Biochemical parameters of bone metabolism (25OHD3, PTH, P1NP, CTX and bALP) were measured at the baseline, and then 1 week and 1, 3, 6 and 12 months. BMD and TBS were obtained by X-ray absorptiometry (DXA) at the baseline and at 6 and 12 months. On DXA image, morphometric vertebral fracture assessment (VFA) was done. RESULTS: There were no significant changes in PTH, bALP or P1NP. A significant drop in CTX was seen at 1 month (down Δ49.31% from the baseline, p = 0.02), with a return to the baseline at the 3-month measurement. There was a moderate (not significant), but persistent reduction in P1NP. No changes in BMD or TBS came to light. No vertebral fractures were documented. CONCLUSIONS: Short-term, high-dose GC treatment caused a rapid, transient suppression of bone resorption, with no effects on BMD or bone micro-architecture (TBS).
Entities:
Keywords:
Bone mineral density; Bone turnover markers; Glucocorticoid
Authors: F Paglia; S Dionisi; S De Geronimo; R Rosso; E Romagnoli; N Raejntroph; A Ragno; M Celi; J Pepe; E D'Erasmo; S Minisola; N Raejentroph Journal: Clin Chem Date: 2001 Impact factor: 8.327
Authors: Alberto Angeli; Giuseppe Guglielmi; Andrea Dovio; Giovanni Capelli; Daniela de Feo; Sandro Giannini; Ruben Giorgino; Luigi Moro; Andrea Giustina Journal: Bone Date: 2006-03-30 Impact factor: 4.398
Authors: Joanna Rymuza; Katarzyna Pelewicz; Jerzy Przedlacki; Piotr Miśkiewicz Journal: Front Endocrinol (Lausanne) Date: 2022-07-14 Impact factor: 6.055
Authors: Pradeesh Sivapalan; Niklas R Jørgensen; Alexander G Mathioudakis; Josefin Eklöf; Therese Lapperre; Charlotte Suppli Ulrik; Helle F Andreassen; Karin Armbruster; Praleene Sivapalan; Julie Janner; Nina Godtfredsen; Ulla M Weinreich; Thyge L Nielsen; Niels Seersholm; Torgny Wilcke; Philipp Schuetz; Tobias W Klausen; Kristoffer Marså; Jørgen Vestbo; Jens-Ulrik Jensen Journal: Respir Res Date: 2020-10-12